FDA buoys Pozen, accepts of amended response

Shares of Pozen rallied 16 percent on news that the FDA had accepted its amended response for the experimental migraine drug Trexima. The amendment was filed in February after Trexima was rejected in December. Pozen has been working with GlaxoSmithKline to gain an approval on Trexima, a combination of Glaxo's Imitrex and the anti-inflammatory naproxen.

- read Pozen's release
- here's the report from LocalTechWire

Related Articles:
FDA green-lights Pozen Phase III. Report
Pozen files NDA for new migraine treatment. Report
Pozen shares sink on new demand for data. Report